Last updated on May 2018

Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age


Brief description of study

This long-term study will provide Elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with Mucopolysaccharidosis II (Hunter syndrome) MPS II.

Clinical Study Identifier: NCT02455622

Contact Investigators or Research Sites near you

Start Over

Barbara Burton

Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, IL United States

Ceila Pérez de Ferrán

Hospital Infantil Dr Robert Reid Cabral
Santo Domingo, Dominican Republic

Julia Hennermann

Universit tsmedizin der Johannes Gutenberg-Universit t Mainz
Mainz, Germany

Lock Hock Ngu

Hospital Kuala Lumpur
Kuala Lumpur, Malaysia

Fathiya Al Murshedi

Sultan Qaboos University Hospital
Sultanate of Oman, Oman

Mary Anne Chiong

Philippine General Hospital
Manila, Philippines

Moeen AlSayed

King Faisal Specialist Hospital & Research Centre
Riyadh, Saudi Arabia

Maja Djordjevic

Mother and Child Health Care Institute of Serbia Dr Vukan Cupic
Beograd, Serbia

Kanya Suphapeetiporn

Chulalongkorn University
Bangkok, Thailand

Vu Chi Dung

National Pediatrics Hospital
Hanoi, Vietnam